Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Classical hematology 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Anemia 1

Interventions

fludarabine phosphate 11Cyclophosphamide 11Whole-Body Irradiation 8Mycophenolic Acid 8Busulfan 7fludarabine 6Tacrolimus 6Peripheral Blood Stem Cell Transplantation 6Melphalan 5Rituximab 4Biopsy 4Azacitidine 4venetoclax 3thymoglobulin 3apixaban 3Methotrexate 3Cyclosporine 3Antilymphocyte Serum 3decitabine and cedazuridine drug combination 2Vorinostat 2Vancomycin 2Tretinoin 2Specimen Handling 2Sirolimus 2Lenalidomide 2Injections 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
luspatercept × Classical hematology × 90 days × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡